Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 451 to 465 of 1255 results for pathway

  1. Eribulin for treating locally advanced or metastatic breast cancer after 1 chemotherapy regimen (TA515)

    Evidence-based recommendations on eribulin (Halaven) for treating locally advanced or metastatic (secondary) breast cancer in adults who have had only 1 course of chemotherapy.

    Technology appraisal guidance
    Published
    28 March 2018
    View recommendations

    Sections for TA515

  2. Midostaurin for treating advanced systemic mastocytosis (TA728)

    Evidence-based recommendations on midostaurin (Rydapt) for treating advanced systemic mastocytosis in adults.

    Technology appraisal guidance
    Published
    22 September 2021
    View recommendations

    Sections for TA728

  3. Nivolumab–relatlimab for untreated unresectable or metastatic melanoma in people 12 years and over (TA950)

    Evidence-based recommendations on nivolumab–relatlimab (Opdualag) for untreated advanced (unresectable or metastatic) melanoma in people 12 years and over.

    Technology appraisal guidance
    Published
    7 February 2024
    View recommendations

    Sections for TA950

  4. Naltrexone–bupropion for managing overweight and obesity (TA494)

    Evidence-based recommendations on naltrexone–bupropion (Mysimba) for managing overweight and obesity in adults.

    Technology appraisal guidance
    Published
    12 December 2017
    View recommendations

    Sections for TA494

  5. End of life care for infants, children and young people (QS160)

    This quality standard covers end of life care for infants, children and young people (from birth to 18 years) who have a life-limiting condition. Life-limiting conditions are those that are expected to result in an early death for the person. It also covers support for family members and carers. It describes high-quality care in priority areas for improvement.

    Quality standard
    Published
    12 September 2017
    View quality statements

    Sections for QS160

  6. Surgical site infection (QS49)

    This quality standard covers preventing and treating surgical site infections. It covers adults, young people and children having a surgical procedure that involves a cut to the skin in all healthcare settings. It describes high-quality care in priority areas for improvement.

    Quality standard
    Published
    31 October 2013
    View quality statements

    Sections for QS49

  7. GreenLight XPS for treating benign prostatic hyperplasia (HTG650)

    Evidence-based recommendations on GreenLight XPS for treating benign prostatic hyperplasia.

    HealthTech guidance
    Published
    29 November 2022
    View recommendations

    Sections for HTG650

  8. Optowire for measuring fractional flow reserve (MIB199)

    NICE has developed a medtech innovation briefing (MIB) on Optowire for measuring fractional flow reserve .

    Medtech innovation briefing
    Published
    3 December 2019

  9. pCONUS2 Bifurcation Aneurysm Implant for complex intracranial aneurysms (MIB222)

    NICE has developed a medtech innovation briefing (MIB) on pCONUS2 Bifurcation Aneurysm Implant for complex intracranial aneurysms .

    Medtech innovation briefing
    Published
    11 August 2020

  10. Aquablation robotic therapy for lower urinary tract symptoms caused by benign prostatic hyperplasia (MIB315)

    NICE has developed a medtech innovation briefing (MIB) on Aquablation robotic therapy for lower urinary tract symptoms caused by benign prostatic hyperplasia .

    Medtech innovation briefing
    Published
    31 January 2023

  11. SecurePort IV tissue adhesive for use with percutaneous catheters (MIB288)

    NICE has developed a medtech innovation briefing (MIB) on SecurePort IV tissue adhesive for use with percutaneous catheters .

    Medtech innovation briefing
    Published
    15 March 2022

  12. Low back pain and sciatica in over 16s: assessment and management (NG59)

    This guideline covers assessing and managing low back pain and sciatica in people aged 16 and over. It outlines physical, psychological, pharmacological and surgical treatments to help people manage their low back pain and sciatica in their daily life. The guideline aims to improve people’s quality of life by promoting the most effective forms of care for low back pain and sciatica.

    NICE guideline
    Last updated
    11 December 2020
    View recommendations

    Sections for NG59

  13. Epilepsies in children, young people and adults (QS211)

    This quality standard covers diagnosing and managing epilepsies in children, young people and adults. It describes high-quality care in priority areas for improvement.

    Quality standard
    Published
    20 December 2023
    View quality statements

    Sections for QS211

  14. Barriers and facilitators:- What are the barriers and facilitators for young people and adults with coexisting severe mental illness and substance misuse to obtain an optimal service (including optimal time frame for delivering interventions) to meet their needs and enable their recovery?

    their family or carers, it is not always clear which point in the care pathway the views and experiences expressed relate to. As such,...

    Research recommendation
    Published
    10 February 2017

  15. Novii Wireless Patch System for maternal and fetal monitoring (MIB228)

    NICE has developed a medtech innovation briefing (MIB) on Novii Wireless Patch System for maternal and fetal monitoring .

    Medtech innovation briefing
    Published
    23 September 2020